Table 1. Relationship between SPAG5 overexpression and the clinicopathological characteristics of ovarian carcinomas patients.
| Groups | No. | SPAG5 | χ2 | P value | |
|---|---|---|---|---|---|
| + | % | ||||
| Total | 102 | 56 | 54.9 | ||
| Age (years) | |||||
| ≥60 | 28 | 16 | 57.1 | 0.08 | 0.780 |
| <60 | 74 | 40 | 54.1 | ||
| Tumor size (cm) | |||||
| >5 | 86 | 49 | 57.0 | 0.95 | 0.329 |
| ≤5 | 16 | 7 | 43.8 | ||
| Histological type | |||||
| Serous | 67 | 42 | 62.7 | 11.53 | 0.009* |
| Mucinous | 17 | 8 | 47.1 | ||
| Endometroid | 13 | 2 | 15.4 | ||
| Clear cell | 5 | 4 | 44.4 | ||
| Pathological grade | |||||
| Grade 1 | 16 | 5 | 31.3 | 4.34 | 0.114 |
| Grade 2 | 21 | 12 | 57.1 | ||
| Grade 3 | 65 | 39 | 60.0 | ||
| Lymph node metastasis | |||||
| Positive | 27 | 25 | 92.6 | 21.07 | 0.001* |
| Negative | 75 | 31 | 41.3 | ||
| Distant metastasis | |||||
| Positive | 21 | 18 | 85.7 | 10.14 | 0.001* |
| Negative | 81 | 38 | 46.9 | ||
| TNM stage | |||||
| Stage I | 3 | 0 | 0.00 | 17.62 | 0.001* |
| Stage II | 21 | 6 | 28.6 | ||
| Stage III | 57 | 32 | 56.1 | ||
| Stage IV | 21 | 18 | 85.7 | ||
| Survival | |||||
| Yes | 43 | 11 | 25.6 | 25.81 | 0.001* |
| No | 59 | 45 | 76.3 | ||
*
P < 0.05